Therapy News and Research

RSS

Discovery Labs awarded NIH Fast Track SBIR grant for developing aerosolized KL4 surfactant for RDS

Discovery Laboratories, Inc. today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS).

16 Dec 2010

RFA highly valuable therapy for controlling cancerous nodules

Researchers from Italy determined that radiofrequency ablation (RFA) is a safe and effective therapy for managing hepatocellular carcinoma (HCC) in cirrhotic patients. The high repeatability of RFA is advantageous in controlling recurrences of cancerous tumors in the liver. Results of this 10-year retrospective study are available in the January 2011 issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

16 Dec 2010

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

16 Dec 2010

RAD to restore SCI's Radiation Treatment Center

Swedish Cancer Institute (SCI) has embarked on a bold approach to rapidly restore community-based radiotherapy cancer treatment in the Ballard community utilizing state-of-the-art building technology that is swift and green.

16 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

WHO report shows significant progress in global malaria fight, highlights need for continued funding

Since 2008, global malaria control efforts have "helped reduce infections across Africa and [eliminate] the disease in Morocco and Turkmenistan, but a slowdown in funding risks undoing those achievements," according to the WHO's annual malaria report, which was released on Tuesday, Reuters reports (Nebehay, 12/14).

16 Dec 2010

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

16 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals.

16 Dec 2010

Use of vitamin K antagonists is driven by availability of oral formulation

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the treatment of atrial fibrillation, surveyed European cardiologists indicate that use of vitamin K antagonists, as a class, is primarily driven by the availability of an oral formulation, overall low cost and widespread inclusion on European medical society guidelines and hospital formularies.

16 Dec 2010

$Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea$

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).

16 Dec 2010

New finding sheds light on how HIV eludes treatment by mutating

The virus that causes AIDS is chameleon-like in its replication. As HIV copies itself in humans, it constantly mutates into forms that can evade even the best cocktail of current therapies. Understanding exactly how HIV cells change as they reproduce is key to developing better tests and treatments for patients.

16 Dec 2010

PEG-Prom encased nanoparticle aids in cancer detection and treatment

In a proof of principal study in mice, scientists at Johns Hopkins and the Virginia Commonwealth University have shown that a set of genetic instructions encased in a nanoparticle can be used as an "ignition switch" to rev up gene activity that aids cancer detection and treatment.

16 Dec 2010

Novel adenovirus-based gene therapy for renal cell carcinoma

Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the primary tumor site but also in distant tumors not directly infected by the virus. Renal cell carcinoma is the most common form of kidney cancer in adults and currently there is no effective treatment for the disease once it has spread outside of the kidney.

16 Dec 2010

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).

16 Dec 2010

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy.

16 Dec 2010

Scientists discover potential strategy for pancreatic cancer therapy

By determining what goes missing in human cells when the gene that is most commonly mutated in pancreatic cancer gets turned on, Johns Hopkins scientists have discovered a potential strategy for therapy.

15 Dec 2010

Experts study obesity in young population with physical, cognitive disabilities

While the nation's obesity epidemic is the target of many programs to combat it, few such programs embrace an often-overlooked subgroup adolescents and young adults with physical or cognitive disabilities.

15 Dec 2010

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Repligen Corporation today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association ("MDA") to support the ongoing development of RG3039 for Spinal Muscular Atrophy ("SMA"). RG3039, our lead compound, is an inhibitor of an RNA processing enzyme which targets increased production of SMN, a protein of deficient levels in patients with SMA.

15 Dec 2010

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.

15 Dec 2010

Therapy News and Research

Discovery Labs awarded NIH Fast Track SBIR grant for developing aerosolized KL4 surfactant for RDS

RFA highly valuable therapy for controlling cancerous nodules

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

RAD to restore SCI's Radiation Treatment Center

Adeona expands and enhances zinc-based product candidate portfolio

WHO report shows significant progress in global malaria fight, highlights need for continued funding

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

Use of vitamin K antagonists is driven by availability of oral formulation

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

New finding sheds light on how HIV eludes treatment by mutating

PEG-Prom encased nanoparticle aids in cancer detection and treatment

Novel adenovirus-based gene therapy for renal cell carcinoma

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

Scientists discover potential strategy for pancreatic cancer therapy

Experts study obesity in young population with physical, cognitive disabilities

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News